Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue

Chemico-Biological Interactions

Volumn 202, Issue 1-3, 2013, Pages 226-233

  Hevir, Neli ^a   Šinkovec, Jasna ^b   Lanišnik Rižner, Tea ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

AKR1B; Cancer; Inflammation; Prostaglandins; Retinoic acid

Indexed keywords

ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1B10; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; AKR1B1 GENE; AKR1B10 GENE; CANCER GROWTH; CARCINOGENESIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME LOCALIZATION; EPITHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS; TISSUE LEVEL; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ALDEHYDE REDUCTASE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; RNA, MESSENGER;

EID: 84875215561     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2012.11.001     Document Type: Conference Paper

References (30)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J. Clin. 55 2 2005 74 108
2. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 9484 2005 491 505
3. N. Samarnthai, K. Hall, and I.T. Yeh Molecular profiling of endometrial malignancies Obstet Gynecol Int 2010 2010 162363
4. T.T. Nieminen, A. Gylling, W.M. Abdel-Rahman, K. Nuorva, M. Aarnio, L. Renkonen-Sinisalo, H.J. Jarvinen, J.P. Mecklin, R. Butzow, and P. Peltomaki Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia Clin. Cancer Res. 15 18 2009 5772 5783
5. M. Inoue Current molecular aspects of the carcinogenesis of the uterine endometrium Int. J. Gynecol. Cancer 11 5 2001 339 348
6. F.S. Liu Molecular carcinogenesis of endometrial cancer Taiwan J. Obstet. Gynecol. 46 1 2007 26 32
7. A.E. Wallace, D.A. Gibson, P.T. Saunders, and H.N. Jabbour Inflammatory events in endometrial adenocarcinoma J. Endocrinol. 206 2 2010 141 157
8. B.E. Henderson, and H.S. Feigelson Hormonal carcinogenesis Carcinogenesis 21 3 2000 427 433
9. T. Lanišnik Rižner Enzymes of the AKR1B and AKR1C subfamilies and uterine diseases Front. Pharmacol. 3 2012 34
10. K.J. Sales, T. List, S.C. Boddy, A.R. Williams, R.A. Anderson, Z. Naor, and H.N. Jabbour A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas Cancer Res. 65 17 2005 7707 7716
11. K.J. Sales, V. Grant, and H.N. Jabbour Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element Mol. Cell. Endocrinol. 285 1-2 2008 51 61
12. J.K. Salabei, X.P. Li, J.M. Petrash, A. Bhatnagar, and O.A. Barski Functional expression of novel human and murine AKR1B genes Chem. Biol. Interact. 191 1-3 2011 177 184
13. O. Gallego, F.X. Ruiz, A. Ardevol, M. Dominguez, R. Alvarez, A.R. de Lera, C. Rovira, J. Farres, I. Fita, and X. Pares Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10 Proc. Natl. Acad. Sci. USA 104 52 2007 20764 20769
14. F.X. Ruiz, S. Porte, X. Pares, and J. Farres Biological role of aldo-keto reductases in retinoic acid biosynthesis and signaling Front. Pharmacol. 3 2012 58
15. Y. Shen, L. Zhong, S. Johnson, and D. Cao Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds Chem. Biol. Interact. 191 1-3 2011 192 198
16. K.V. Ramana Aldose reductase: new insights for an old enzyme Biomol. Concepts 2 1-2 2011 103 114
17. O.A. Barski, S.M. Tipparaju, and A. Bhatnagar The aldo-keto reductase superfamily and its role in drug metabolism and detoxification Drug Metab. Rev. 40 4 2008 553 624
18. C. Yabe-Nishimura Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications Pharmacol. Rev. 50 1 1998 21 33
19. E. Bresson, S. Boucher-Kovalik, P. Chapdelaine, E. Madore, N. Harvey, P.Y. Laberge, M. Leboeuf, and M.A. Fortier The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium J. Clin. Endocrinol. Metab. 96 1 2011 210 219
20. Z. Kabututu, M. Manin, J.C. Pointud, T. Maruyama, N. Nagata, S. Lambert, A.M. Lefrancois-Martinez, A. Martinez, and Y. Urade Prostaglandin F2alpha synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7 J. Biochem. 145 2 2009 161 168
21. R. Tammali, S.K. Srivastava, and K.V. Ramana Targeting aldose reductase for the treatment of cancer Curr. Cancer Drug Targets 11 5 2011 560 571
22. T. Matsunaga, Y. Wada, S. Endo, M. Soda, O. El-Kabbani, and A. Hara Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers Front. Pharmacol. 3 2012 5
23. L. Zhong, H. Shen, C. Huang, H. Jing, and D. Cao AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group Toxicol. Appl. Pharmacol. 255 1 2011 40 47
24. B. Laffin, and J.M. Petrash Expression of the aldo-keto reductases AKR1B1 and AKR1B10 in human cancers Front. Pharmacol. 3 2012 104
25. D.X. Luo, M.C. Huang, J. Ma, Z. Gao, D.F. Liao, and D. Cao Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway Biochem. J. 438 1 2011 71 80
26. N. Hevir, J. Sinkovec, and T.L. Rizner Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT Mol. Cell. Endocrinol. 331 1 2011 158 167
27. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, and F. Speleman Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 7 2002 (RESEARCH0034)
28. S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, G.L. Shipley, J. Vandesompele, and C.T. Wittwer The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments Clin. Chem. 55 4 2009 611 622
29. P. Alexiou, K. Pegklidou, M. Chatzopoulou, I. Nicolaou, and V.J. Demopoulos Aldose reductase enzyme and its implication to major health problems of the 21(st) century Curr. Med. Chem. 16 6 2009 734 752
30. H. Yoshitake, M. Takahashi, H. Ishikawa, M. Nojima, H. Iwanari, A. Watanabe, H. Aburatani, K. Yoshida, K. Ishi, K. Takamori, H. Ogawa, T. Hamakubo, T. Kodama, and Y. Araki Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer Int. J. Gynecol. Cancer 17 6 2007 1300 1306